Overview
| Product name | Recombinant Human Granzyme B/CTLA-1/GZMB Protein |
|---|
| Catalog No. | RP02860 |
|---|
| Description | Recombinant Human Granzyme B Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gly19-Tyr247) of human Granzyme B (Accession #NP_004122.1) fused with a 6×His tag at the C-terminus. |
|---|
| Bio-Activity | Measured by its ability to cleave a peptide substrate, tButyloxycaronylAlaAlaAspThioBenzylester (BocAADSBzl), in the presence of 5, 5’Dithiobis (2nitrobenzoic acid) (DTNB). The specific activity is >1500 pmol/min/μg. (The enzyme needs to be activated by Recombinant Mouse Active Cathepsin C)
|
|---|
| Purity | >97% as determined by SDS-PAGE |
|---|
| Endotoxin | <1EU/μg |
|---|
| Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation. |
|---|
| Species | Human |
|---|
| Calculated MW | 26.57 kDa |
|---|
Background
Granzyme B, also known as GZMB, is the most prominent member of the granzyme family of cell death-inducing serine proteases expressed in the granules of cytotoxic T lymphocytes (CTLs) and NK cells. Granzyme B enters the target cells depending on another membrane-binding granule protein, perforin, results in the activation of effector caspases and mitochondrial depolarization through caspase-dependent and -independent pathways, and consequently induces rapid cell apoptosis. Over 3 substrates of GZMB have been identified including the key substrate caspase-3, ICAD, and Bid. GZMB is suggested to protect the host by lysing cells bearing on their surface 'nonself' antigens such as bacterial and viral infected-cells and tumor cells and accordingly plays an essential role in immunosurveillance.
Product information
| Synonym | C11; HLP; CCPI; CGL1; CSPB; SECT; CGL-1; CSP-B; CTLA1; CTSGL1; GZMB |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-His |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
